Mirador Therapeutics

Mirador360 brings data, science and strategy together in one engine—anchored by three principles:

Advancing multiple programs across Crohn’s disease, ulcerative colitis, rheumatoid arthritis, and idiopathic pulmonary fibrosis; 10+ clinical readouts expected by year-end 2027

Mirador develops therapeutics using its Mirador360 precision development engine, which integrates human genetics and data science.

Mirador focuses on advancing precision medicine in immunology and inflammation, aiming to drive innovation in the field.

Allison Luo, M.D., is an experienced biotech executive who has successfully led many clinical programs. Most recently, she served as Chief Medical Officer of Prometheus Biosciences from August 2018 through the company’s sale to Merck in 2023.

The leadership team combines expertise in drug development, translational immunology, data science, and company building to advance precision medicine in healthcare.

Mark C. McKenna is a luminary biotech entrepreneur, executive and director with a track record of delivering exceptional results for investors and patients.

Olivier Laurent, Ph.D., is a seasoned biotech-pharma R&D leader with deep experience in drug development and bioinformatics.

Chronic immuno-fibrotic diseases remain difficult to treat, with many patients showing insufficient or lost response to approved therapies. Precision medicine in immunology and inflammation aims to address this unmet need through personalized therapies.

4902 Headquarters Point Suite 300 San Diego, CA 92121

Mirador aims to overcome current treatment limitations in immunology and inflammation by targeting specific patient needs and developing precision medicines.